Site Search

The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.

Microplastics are plastic particles found across the environment—in water supplies, food sources, and human tissue—and have emerged as a frontline legal and regulatory issue. The science is developing quickly, and regulatory and litigation activity is following close behind, from EPA's inclusion of microplastics on its draft Sixth Contaminant Candidate List (CCL 6) as a priority contaminant group to growing state legislation and an expanding wave of private litigation. Companies across industries are facing increasing uncertainty and risk.

Every deal has a lifecycle — and at each stage, competition law and foreign direct investment (FDI) rules have the potential to change the outcome. Knowing where the risks lie, and how to manage them, can make all the difference. Join us for a practical session in which we will guide you through the full lifecycle of a deal from a competition and FDI perspective.